Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 9/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 2/20 | 0.50 |
| ▸ | FADS1 | O60427 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27684193 | 0.93 | NPC1 (0.57) | CHRM1CHRM2CHRM4CHRM3CNR2 | |
| SCHEMBL15534964 | 0.89 | HTR4 (0.47) | CHRM1CHRM2CHRM4CHRM3CNR2 | |
| SCHEMBL15534965 | 0.89 | HTR4 (0.47) | CHRM1CHRM2CHRM4CHRM3CNR2 | |
| SCHEMBL4845927 | 0.83 | CHRM1 (0.58) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL17434345 | 0.80 | ALDH1A1 (0.57) | CCR2POLB | |
| SCHEMBL14734915 | 0.79 | CNR2 (0.49) | CHRM1CHRM2CHRM4CHRM3CNR2 | |
| SCHEMBL6205964 | 0.78 | CCR2 (0.81) | CCR2HTR4 | |
| SCHEMBL11689255 | 0.78 | NOS2 (0.63) | CCR2FADS1POLB | |
| SCHEMBL2154639 | 0.78 | ALDH1A1 (0.56) | CHRM1CHRM2CHRM4CHRM3NPC1 | |
| SCHEMBL14686258 | 0.78 | CNR2 (0.60) | CHRM1CNR2NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103204811-B | Process for production of anthranilamide compound | ISHIHARA SANGYO KAISHA | 2015-02-04 | — | — | CN | disclosed |
| EP-2093223-B1 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA (JP) | 2013-08-21 | — | — | EP | disclosed |
| CN-103204811-A | Process For Production Of Anthranilamide Compound | ISHIHARA SANGYO KAISHA | 2013-07-17 | — | — | CN | disclosed |
| CN-101558056-B | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA | 2013-05-01 | — | — | CN | disclosed |
| US-8115006-B2 | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100063293-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA ,LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| CN-101558056-A | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA (JP) | 2009-10-14 | — | — | CN | disclosed |
| EP-2093223-A1 | PROCESS FOR PRODUCTION OF ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2009-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063293-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | NAAA, AAAS, AADAC | CHRM1 2756/4885CHRM2 3112/4885CHRM4 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.